The Lazcluze plus Rybrevant combination could challenge AstraZeneca’s standard-of-care Tagrisso in non-small cell lung cancer ...

First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or metastatic NSCLC.

The European Commission (EC) has approved a Marketing Authorization (MA) for Lazcluze (lazertinib), in combination with ...

Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...

As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & ...

Johnson & Johnson's recently approved combination of Rybrevant and Lazcluze has improved overall survival compared to AstraZeneca's Tagrisso in a head-to-head trial, claiming what could be a key ...

Results from the Mariposa study found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced lung cancer live longer.

Johnson & Johnson announced positive topline results for the gold standard endpoint in cancer treatment of overall survival, or OS, from ...

(RTTNews) - Johnson & Johnson (JNJ) on Tuesday announced positive topline results from the Phase 3 MARIPOSA study, highlighting the combination of RYBREVANT and LAZCLUZE as a first-line therapy ...